Drug Profile
Temozolomide gel - Double Bond Pharmaceutical
Alternative Names: SI 053; TemodexLatest Information Update: 08 Aug 2022
Price :
$50
*
At a glance
- Originator Research Institute for Physical Chemical Problems of the Belarusian State University
- Developer Double Bond Pharmaceutical; RUE Belmedpreparaty
- Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Imidazoles; Small molecules; Triazenes
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Glioblastoma
Most Recent Events
- 27 May 2022 Double Bond Pharmaceutical has patent protection for temozolomide gel in Japan
- 27 May 2022 Double Bond Pharmaceutical receives positive response from regulatory authority Federal Institute for Drugs and Medical Devices (BfArM) to start clinical trial in Germany
- 27 May 2022 Double Bond Pharmaceutical plans a clinical trial for Glioblastoma in Germany